📊 LIXT Key Takeaways
Is Lixte Biotechnology Holdings, Inc.. (LIXT) a Good Investment?
LIXT is a pre-commercial biotech firm burning $1.8M in quarterly operating cash against only $200K in revenue, with approximately 6-7 months of cash runway remaining despite maintaining a debt-free balance sheet. Absent near-term successful product commercialization, strategic partnerships, or capital raise announcements, the company faces acute funding risk and potential equity depletion within two quarters.
Fundamentals indicate a pre‑commercial biotech with minimal revenue and extremely negative margins, ROE, and ROA. Liquidity is solid and the balance sheet is debt‑free, but the current cash burn implies a limited runway and likely need for external financing. Until operating losses narrow materially or recurring revenue emerges, downside risk from dilution and execution remains high.
Lixte Biotechnology Holdings, Inc.. Key Strengths (LIXT)
- Debt-free balance sheet with zero long-term debt and positive stockholders' equity of $7.9M
- Strong liquidity position with 2.78x current ratio providing near-term operational flexibility
- 6 Form 4 insider filings in 90 days indicate continued insider engagement
- Debt-free balance sheet
- Strong liquidity (current ratio ~3.9x)
- Positive equity relative to low liabilities
LIXT Stock Risks: Lixte Biotechnology Holdings, Inc.. Investment Risks
- Critical cash runway depletion: $3.3M reserve at $1.8M quarterly burn rate leaves 6-7 months of operational capacity before funding crisis
- Pre-commercial revenue stage: $200K quarterly revenue indicates zero successful product commercialization and non-viable business model at current scale
- Structural operating losses: -993.7% operating margin and -970.8% net margin reflect fundamental inability to generate positive unit economics
- Sustained operating losses with minimal revenue base
- Cash burn likely necessitating dilutive financing
- Execution/clinical milestone risk impacting funding and timing
Key Metrics to Watch
- Quarterly cash balance and monthly burn rate trend
- Product revenue growth and commercialization progress
- Capital raise announcements, partnerships, or strategic transactions
- Operating cash burn (OCF)
- Cash and equivalents / runway months
Lixte Biotechnology Holdings, Inc.. (LIXT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.78x current ratio provides a solid financial cushion.
LIXT Profit Margin, ROE & Profitability Analysis
LIXT vs Healthcare Sector: How Lixte Biotechnology Holdings, Inc.. Compares
How Lixte Biotechnology Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lixte Biotechnology Holdings, Inc.. Stock Overvalued? LIXT Valuation Analysis 2026
Based on fundamental analysis, Lixte Biotechnology Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lixte Biotechnology Holdings, Inc.. Balance Sheet: LIXT Debt, Cash & Liquidity
LIXT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lixte Biotechnology Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.59 indicates the company is currently unprofitable.
LIXT Revenue Growth, EPS Growth & YoY Performance
LIXT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2013 | N/A | -$16.1K | N/A |
| Q2 2013 | N/A | -$16.1K | N/A |
| Q1 2013 | N/A | -$16.1K | N/A |
| Q3 2012 | N/A | -$16.1K | N/A |
| Q2 2012 | N/A | -$16.1K | N/A |
| Q1 2012 | N/A | -$16.1K | N/A |
| Q3 2011 | N/A | -$16.1K | N/A |
| Q2 2011 | N/A | -$16.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lixte Biotechnology Holdings, Inc.. Dividends, Buybacks & Capital Allocation
LIXT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lixte Biotechnology Holdings, Inc.. (CIK: 0001335105)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIXT
What is the AI rating for LIXT?
Lixte Biotechnology Holdings, Inc.. (LIXT) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIXT's key strengths?
Claude: Debt-free balance sheet with zero long-term debt and positive stockholders' equity of $7.9M. Strong liquidity position with 2.78x current ratio providing near-term operational flexibility. ChatGPT: Debt-free balance sheet. Strong liquidity (current ratio ~3.9x).
What are the risks of investing in LIXT?
Claude: Critical cash runway depletion: $3.3M reserve at $1.8M quarterly burn rate leaves 6-7 months of operational capacity before funding crisis. Pre-commercial revenue stage: $200K quarterly revenue indicates zero successful product commercialization and non-viable business model at current scale. ChatGPT: Sustained operating losses with minimal revenue base. Cash burn likely necessitating dilutive financing.
What is LIXT's revenue and growth?
Lixte Biotechnology Holdings, Inc.. reported revenue of $200.0K.
Does LIXT pay dividends?
Lixte Biotechnology Holdings, Inc.. does not currently pay dividends.
Where can I find LIXT SEC filings?
Official SEC filings for Lixte Biotechnology Holdings, Inc.. (CIK: 0001335105) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIXT's EPS?
Lixte Biotechnology Holdings, Inc.. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LIXT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Lixte Biotechnology Holdings, Inc.. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LIXT stock overvalued or undervalued?
Valuation metrics for LIXT: ROE of -24.4% (sector avg: 15%), net margin of -970.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LIXT's AI grade for 2026?
Our dual AI analysis gives Lixte Biotechnology Holdings, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIXT's free cash flow?
Lixte Biotechnology Holdings, Inc..'s operating cash flow is $-1.8M, with capital expenditures of N/A. FCF margin is -915.7%.
How does LIXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -970.8% (avg: 12%), ROE -24.4% (avg: 15%), current ratio 2.78 (avg: 2).